You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Drug Minimizes Risk of Blood Clots in Atrial Fibrillation

Aschenbrenner, Diane S. MS, APRN-BC

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000394286.02212.73
Drug Watch
Abstract

* Dabigatran etexilate (Pradaxa) has been approved to lower the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation.

* In clinical trials, patients taking dabigatran had fewer ischemic and hemorrhagic strokes than patients taking warfarin.

* As with other anticoagulants, dabigatran may cause serious, even fatal, bleeding.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2011 Lippincott Williams & Wilkins, Inc.